MedPath

Ludwig Institut für Krebsforschung AG

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
-
Website

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Phase 1
Completed
Conditions
Breast Cancer
Renal Cell Carcinoma
Ovarian Cancer
Cervical Cancer
Colorectal Cancer
Interventions
First Posted Date
2013-11-05
Last Posted Date
2022-10-12
Lead Sponsor
Ludwig Institute for Cancer Research
Target Recruit Count
104
Registration Number
NCT01975831
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

University of Virginia Division of Hematology and Oncology, Charlottesville, Virginia, United States

and more 3 locations

Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma

Phase 1
Terminated
Conditions
Metastatic Melanoma
Interventions
Biological: Bacillus Calmette-Guérin (BCG) vaccine
Drug: Ipilimumab
Drug: Isoniazid
First Posted Date
2013-04-23
Last Posted Date
2022-10-12
Lead Sponsor
Ludwig Institute for Cancer Research
Target Recruit Count
5
Registration Number
NCT01838200
Locations
🇦🇺

Austin Health, LICR Melbourne Austin Branch, Heidelberg, Victoria, Australia

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Phase 1
Terminated
Conditions
Unresectable or Metastatic Melanoma
Interventions
Biological: Ipilimumab
Biological: NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide
Biological: NY-ESO-1 OLP4 Vaccine with Poly-ICLC
Biological: NY-ESO-1 Protein Vaccine
First Posted Date
2013-03-13
Last Posted Date
2022-10-12
Lead Sponsor
Ludwig Institute for Cancer Research
Target Recruit Count
8
Registration Number
NCT01810016
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

Mount Sinai Medical Center, New York, New York, United States

🇺🇸

University of Virginia Cancer Center, Charlottesville, Virginia, United States

and more 2 locations

Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma

Phase 1
Withdrawn
Conditions
Metastatic Melanoma
Interventions
Drug: Anti-OX40
Drug: Ipilimumab
First Posted Date
2012-09-21
Last Posted Date
2014-04-01
Lead Sponsor
Ludwig Institute for Cancer Research
Registration Number
NCT01689870

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

Phase 1
Withdrawn
Conditions
Solid Tumors
Lymphomas
Interventions
Drug: Recombinant human TNF-α
Drug: Liposomal doxorubicin
Drug: Caelyx
First Posted Date
2011-12-12
Last Posted Date
2015-06-16
Lead Sponsor
Ludwig Institute for Cancer Research
Registration Number
NCT01490047
Locations
🇩🇪

Krankenhaus Nordwest, Frankfurt, Germany

MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Biological: recMAGE-A3 Protein + AS15 Adjuvant
First Posted Date
2011-06-27
Last Posted Date
2022-10-25
Lead Sponsor
Ludwig Institute for Cancer Research
Target Recruit Count
13
Registration Number
NCT01380145
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

New York University School of Medicine, New York, New York, United States

and more 1 locations

Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

Phase 2
Terminated
Conditions
Small Cell Lung Cancer
Interventions
Drug: ADI-PEG 20 (Arginine deiminase pegylated)
First Posted Date
2010-12-24
Last Posted Date
2022-10-25
Lead Sponsor
Ludwig Institute for Cancer Research
Target Recruit Count
22
Registration Number
NCT01266018
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇨🇳

National Taiwan University Hospital, Taipei City, Taiwan

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 5 locations

A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

Phase 1
Completed
Conditions
Colorectal Neoplasms
Interventions
Drug: CS-1008
First Posted Date
2010-10-14
Last Posted Date
2022-10-28
Lead Sponsor
Ludwig Institute for Cancer Research
Target Recruit Count
19
Registration Number
NCT01220999
Locations
🇦🇺

Ludwig Institute Tumor Targeting Program, Austin Health, Melbourne, Victoria, Australia

Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Phase 1
Completed
Conditions
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cavity Cancer
Interventions
Biological: ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine
Biological: Sargramostim
First Posted Date
2008-12-05
Last Posted Date
2023-10-04
Lead Sponsor
Ludwig Institute for Cancer Research
Target Recruit Count
13
Registration Number
NCT00803569
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

🇺🇸

NYU Cancer Institute at New York University Medical Center, New York, New York, United States

Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma

Phase 2
Completed
Conditions
Metastatic Melanoma
Cutaneous Melanoma
Interventions
Drug: HDI
Drug: KW2871
First Posted Date
2008-05-16
Last Posted Date
2022-10-12
Lead Sponsor
Ludwig Institute for Cancer Research
Target Recruit Count
36
Registration Number
NCT00679289
Locations
🇺🇸

University of Chicago Hospital, Chicago, Illinois, United States

🇺🇸

University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath